Abstract: The present disclosure provides advantageous hybrid knitted fabrics and composite materials including hybrid knitted fabrics, and improved systems/methods for utilizing and/or fabricating the hybrid knitted fabrics and composite materials. More particularly, the present disclosure provides layered composite materials including hybrid knitted fabrics, the layered composite materials advantageously configured for non-score deployable passenger airbag applications.

Abstract: Disclosed are hydroquinone compounds, preparation methods therefor, and uses thereof in anti-tumor or immunomodulation. The structural formula of the hydroquinone compounds are shown by formula I, wherein X is C?O or CH2; Y is NH, O or absent; R is: a substituted or unsubstituted alkyl group having at least one carbon atom, a substituted or unsubstituted cycloalkyl group having at least three carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having at least two carbon atoms; and a substituted or unsubstituted aryl group or heteroaryl group containing at least four carbon atoms. The compounds provided slowly release 2-tert-butyl-4-methoxyphenol in vivo and maintain stable plasma concentration of 2-tert-butyl-4-methoxyphenol (T1/2=12-24 h). The compounds provided by the present invention protect the phenolic hydroxyl group of 2-tert-butyl-4-methoxyphenol, avoids environmental oxidation and increase the environmental stability of drugs containing the compounds.

Abstract: The present invention relates to a stable crystal form, i.e. form A, of 2-tert-butyl-4-methoxyphenol, and to a new preparation method for the 2-tert-butyl-4-methoxyphenol; and the use of the 2-tert-butyl-4-methoxyphenol and the stable crystal form thereof, i.e. form A, in preparing antitumor drugs or immunomodulator drugs. The stable crystal form, i.e. form A, as expressed by a powder X-ray diffraction pattern in an angle of 2?, using Cu-K? radiation, has at least 3 absorption peaks selected from the following positions: 6.27±0.10, 6.94±0.10, 12.27±0.10, 13.36±0.10, 14.01±0.10, 14.79±0.10, 15.31±0.10, 17.05±0.10, 18.30±0.10, 19.00±0.10, 20.47±0.10, 20.98±0.10, 22.37±0.10, 23.68±0.10, 24.55±0.10, 25.37±0.10, 30.83±0.10, 33.12±0.10, 40.50±0.10, 42.81±0.10.

Abstract: A cooking appliance includes a base, a cover body pivotally mounted at the base, a pivot spring provided at a pivot connection member between the base and the cover body, and an attraction assembly including a first attraction member provided at the base and a second attraction member provided at the cover body. The first attraction member and the second attraction member are configured to attract each other to lock the cover body to the base.

Abstract: The present invention relates to a stable crystal form, i.e. form A, of 2-tert-butyl-4-methoxyphenol, and to a new preparation method for the 2-tert-butyl-4-methoxyphenol; and the use of the 2-tert-butyl-4-methoxyphenol and the stable crystal form thereof, i.e. form A, in preparing antitumor drugs or immunomodulator drugs. The stable crystal form, i.e. form A, as expressed by a powder X-ray diffraction pattern in an angle of 2?, using Cu-K? radiation, has at least 3 absorption peaks selected from the following positions: 6.27±0.10, 6.94±0.10, 12.27±0.10, 13.36±0.10, 14.01±0.10, 14.79±0.10, 15.31±0.10, 17.05±0.10, 18.30±0.10, 19.00±0.10, 20.47±0.10, 20.98±0.10, 22.37±0.10, 23.68±0.10, 24.55±0.10, 25.37±0.10, 30.83±0.10, 33.12±0.10, 40.50±0.10, 42.81±0.10.

Abstract: A vehicular trim component including a substrate and a continuous flexible surface layer wherein at least a portion of the continuous flexible surface layer has a visible light transmission of 5 to 30% as determined by ASTM D1003 or a visible light transmission greater than or equal to 80% as determined by ASTM D1003. Optionally a flexible backing layer may be disposed between the substrate and the continuous flexible surface layer.

Abstract: Disclosed are hydroquinone compounds, preparation methods therefor, and uses thereof in anti-tumor or immunomodulation. The structural formula of the hydroquinone compounds are shown by formula I, wherein X is C?O or CH2; Y is NH, O or absent; R is: a substituted or unsubstituted alkyl group having at least one carbon atom, a substituted or unsubstituted cycloalkyl group having at least three carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having at least two carbon atoms; and a substituted or unsubstituted aryl group or heteroaryl group containing at least four carbon atoms. The compounds provided slowly release 2-tert-butyl-4-methoxyphenol in vivo and maintain stable plasma concentration of 2-tert-butyl-4-methoxyphenol (T1/2=12-24 h). The compounds provided by the present invention protect the phenolic hydroxyl group of 2-tert-butyl-4-methoxyphenol, avoids environmental oxidation and increase the environmental stability of drugs containing the compounds.

Abstract: A cooking appliance includes a base, a cover body pivotally mounted at the base, a pivot spring provided at a pivot connection member between the base and the cover body, and an attraction assembly including a first attraction member provided at the base and a second attraction member provided at the cover body. The first attraction member and the second attraction member are configured to attract each other to lock the cover body to the base.

Abstract: Disclosed are hydroquinone compounds, preparation methods therefor, and uses thereof in anti-tumor or immunomodulation. The structural formula of the hydroquinone compounds are shown by formula I, wherein X is C?O or CH2; Y is NH, O or absent; R is a substituted or unsubstituted alkyl group having at least one carbon atom, a substituted or unsubstituted cycloalkyl group having at least three carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having at least two carbon atoms; and a substituted or unsubstituted aryl group or heteroaryl group containing at least four carbon atoms. The compounds provided slowly release 2-tert-butyl-4-methoxyphenol in vivo and maintain stable plasma concentration of 2-tert-butyl-4-methoxyphenol (T½=12˜24 h). The compounds provided by the present invention protect the phenolic hydroxyl group of 2-tert-butyl-4-methoxyphenol, avoid environmental oxidation and increase the environmental stability of drugs containing the compounds.

Abstract: Disclosed are hydroquinone compounds, preparation methods therefor, and uses thereof in anti-tumor or immunomodulation. The structural formula of the hydroquinone compounds are shown by formula I, wherein X is C?O or CH2; Y is NH, O or absent; R is a substituted or unsubstituted alkyl group having at least one carbon atom, a substituted or unsubstituted cycloalkyl group having at least three carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having at least two carbon atoms; and a substituted or unsubstituted aryl group or heteroaryl group containing at least four carbon atoms. The compounds provided slowly release 2-tert-butyl-4-methoxyphenol in vivo and maintain stable plasma concentration of 2-tert-butyl-4-methoxyphenol (T½=12˜24 h). The compounds provided by the present invention protect the phenolic hydroxyl group of 2-tert-butyl-4-methoxyphenol, avoid environmental oxidation and increase the environmental stability of drugs containing the compounds.

Abstract: Disclosed herein is a method of making a melt-processable material comprises: processing a cross-linked polymeric foam to form a processed cross-linked polymeric foam material wherein the processed cross-linked polymeric foam material has an average particle size suitable for feeding to a melt processor, feeding the processed cross-linked polymeric foam material to the melt processor, and melt mixing a composition comprising the processed cross-linked polymeric foam material and a thermoplastic material wherein the processed cross-linked foam material has a domain size, under melt mixing conditions, less than or equal to the processing spaces of the melt processor.

Abstract: Devices of the invention are portable speakers that provide stereophonic, surround sound. According to certain aspects, a speaker system includes a first speaker portion, a second speaker portion and a cable handle. The first speaker portion includes a first end and a second end, and the second speaker portion includes a third end and a fourth end. The cable handle couples the first end of the first speaker portion and a third end of the second speaker portion. The second end of the first speaker portion is configured to releasably couple to the fourth end of the second speaker portion, thereby forming a looped unit, when coupled, with the first speaker portion, the second speaker portion, and the cable handle.

Abstract: Disclosed herein is a method of making a melt-processable material comprises: processing a cross-linked polymeric foam to form a processed cross-linked polymeric foam material wherein the processed cross-linked polymeric foam material has an average particle size suitable for feeding to a melt processor, feeding the processed cross-linked polymeric foam material to the melt processor, and melt mixing a composition comprising the processed cross-linked polymeric foam material and a thermoplastic material wherein the processed cross-linked foam material has a domain size, under melt mixing conditions, less than or equal to the processing spaces of the melt processor.

Abstract: The present invention relates to an acyclic nucleoside phosphonate derivative and medical uses thereof. Specifically, the present invention relates to an acyclic nucleoside phosphonate derivative of Formula I having strong potency against viruses, such as hepatitis B virus, and low cytotoxicity, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, wherein R1 is H or methyl; each R2 is independently —R3 or —OR3, each R3 is independently C1-C8 alkyl, C3-C8 cycloalkyl. The present invention further relates to a process for preparing the compounds of Formula I, a pharmaceutical composition comprising the compound, and the medical uses of the compound. The acyclic nucleoside phosphonate derivative of the present invention has activity against virus such as hepatitis B virus and good in vivo behavioral traits.

Abstract: Devices of the invention are portable speakers that provide stereophonic, surround sound. According to certain aspects, a speaker system includes a first speaker portion, a second speaker portion and a cable handle. The first speaker portion includes a first end and a second end, and the second speaker portion includes a third end and a fourth end. The cable handle couples the first end of the first speaker portion and a third end of the second speaker portion. The second end of the first speaker portion is configured to releasably couple to the fourth end of the second speaker portion, thereby forming a looped unit, when coupled, with the first speaker portion, the second speaker portion, and the cable handle.

Abstract: A vehicle door latch system configured to temporarily prevent door latch mechanisms from unlatching during a predetermined event is provided. The vehicle door latch system includes a forkbolt pivotally mounted to a housing portion of the vehicle door latch. The forkbolt is capable of moving between a latching position and an unlatching position. The door latch system also includes a block out mechanism configured for movement between a blocking position and an unblocking position. The block out mechanism is configured to prevent the forkbolt from moving from the latching position to the unlatching position when the block out mechanism is in the blocking position. A biasing member biases the block out mechanism into the unblocking position.

Abstract: The present invention relates to an acyclic nucleoside phosphonate derivative and medical uses thereof. Specifically, the present invention relates to an acyclic nucleoside phosphonate derivative of Formula I having strong potency against viruses, such as hepatitis B virus, and low cytotoxicity, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, wherein R1 is H or methyl; each R2 is independently —R3 or —OR3, each R3 is independently C1-C8 alkyl, C3-C8 cycloalkyl. The present invention further relates to a process for preparing the compounds of Formula I, a pharmaceutical composition comprising the compound, and the medical uses of the compound. The acyclic nucleoside phosphonate derivative of the present invention has activity against virus such as hepatitis B virus and good in vivo behavioral traits.

Abstract: The present invention relates to a new amine compound or a pharmaceutically acceptable salt thereof, wherein the definitions of X, R1, R2 and n are given in the description, to a pharmaceutical composition containing the compound as active ingredient, and to use of the amine compound or its pharmaceutically acceptable salt for the manufacture of an anti-depressent drug.

Abstract: The present invention relates to a new amine compound or a pharmaceutically acceptable salt thereof, wherein the definitions of X, R1, R2 and n are given in the description, to a pharmaceutical composition containing the compound as active ingredient, and to use of the amine compound or its pharmaceutically acceptable salt for the manufacture of an anti-depressent drug.

Abstract: A cinching latch assembly is disclosed herein. The cinching latch assembly having: a housing; a unidirectional motor mounted to the housing; at least one gear operatively connected to the unidirectional motor; at least one cam member operatively connected to the at least one gear; and a latch lever pivotally mounted relative to the housing, the latch lever being operatively connected to the at least one cam member wherein, operation of the unidirectional motor in a first direction rotates the gear causing the cam member to urge the latch lever between a first position and a second position wherein the latch lever rotates a fork bolt into a primary latched configuration.